APOE and Cognitive impairment: Notably, although APOE ε4 carriers generally showed higher point estimates of cognitive impairment risk than non-carriers with the same PA categories, we found no significant difference in the risk between carriers with high PA levels and non-carriers with high PA levels (P-value > 0.05).